Zydus Lifesciences Limited has informed the Exchange about Investor Presentation
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences filed its investor presentation ahead of a three-day investor conference. The deck highlights FY25 revenues of Rs. 225.7 bn (US$ 2.75 bn) with EBITDA margin of 30.4% and a net cash balance sheet (Net Debt/EBITDA of -0.69). Business segments India Formulations (~10% CAGR) and US Formulations (~15% CAGR) are key growth drivers, with the US business ranked #5 by prescriptions. The company showcased 207 products in its US generics pipeline (addressable market ~US$ 170 bn), 14 biosimilars launched, and a robust NCE pipeline including Saroglitazar for MASH/PBC with US Phase II(b)/III readout expected by end-CY2025. It also detailed its MedTech foray via the proposed Amplitude Surgical acquisition (orthopaedics platform) and the recently signed Agenus biologics CDMO deal for US$ 75 mn upfront.
The presentation reinforces Zydus' positioning as a differentiated, innovation-led pharma player with strong margin trajectory and net cash on books, which is likely to be viewed positively by investors. Key near-term catalysts include the Saroglitazar MASH Phase III readout, US pipeline approvals, and closure of the Amplitude Surgical acquisition, all of which could support re-rating.